Islamabad: Pakistan is taking significant steps toward improving access to insulin for diabetic patients. Special Assistant to the Prime Minister (SAPM) on Industries and Production, Haroon Akhtar Khan, announced on Wednesday that a pharmaceutical joint venture between Pakistan and Russia will play a key role in this initiative.
The SAPM led a high-level meeting attended by Denis Nazarov, a representative of the Russian government, alongside senior officials from the Ministry of Industries and Production, Ministry of National Health Services, and the Drug Regulatory Authority of Pakistan (DRAP). The primary focus of the discussions was the import of insulin from Russia, the progress on ongoing pharmaceutical joint ventures, and the development of regulatory protocols for the implementation of a comprehensive policy board.
Focus on Insulin Imports and Joint Ventures
A major highlight of the meeting was DRAP’s decision to grant registration to Genetics Pharmaceuticals, Lahore, allowing the company to import insulin from Zavod Medsintez, a Russian pharmaceutical manufacturer. This move is seen as a positive step in addressing Pakistan’s growing demand for insulin. Pakistan has one of the largest diabetic populations in the world, making the regular and reliable supply of insulin critical for managing diabetes nationwide.
Khan emphasized the importance of ensuring that diabetic patients have access to affordable insulin, a life-saving medication that is essential for those suffering from Type 1 and Type 2 diabetes. He expressed confidence that importing insulin from Russia would significantly improve the situation for diabetic patients in the country.
Advancing Local Production
Aligned with Prime Minister Shehbaz Sharif’s vision, Haroon Akhtar Khan revealed that steps are being taken to initiate the domestic production of insulin in Pakistan. The government is in the process of finalizing a collaborative agreement between local pharmaceutical companies and Russian firms. This collaboration is anticipated to lead to the establishment of local insulin production facilities, which will reduce reliance on imports and help maintain a consistent supply of insulin throughout the country.
Khan also called for the creation of a detailed proposal by all relevant stakeholders, which will then be presented to the Federal Cabinet for approval. Once approved, the initiative will mark a significant leap forward in Pakistan’s pharmaceutical industry and its ability to meet domestic healthcare needs more effectively.
Ensuring Sustainable Solutions
This move toward local manufacturing of insulin reflects a broader strategy by the government to boost the domestic pharmaceutical industry and reduce the reliance on foreign imports. By fostering joint ventures with international companies, Pakistan aims to build a sustainable, self-sufficient pharmaceutical sector that can meet the country’s growing healthcare demands.
The establishment of local insulin production facilities will also create new job opportunities and contribute to the economic growth of the country. By ensuring a reliable, local supply of insulin, Pakistan can provide its citizens with the treatment they need while strengthening its pharmaceutical industry.
Comments are closed.